Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to p ...

B. Riley decreased their FY2027 earnings estimates for shares of Geron in a research note issued to investors on Tuesday, ...

B. Riley dropped their FY2025 earnings per share (EPS) estimates for shares of Geron in a research report issued to clients ...

Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity ...